Industry Report — IR-001

Who Is Buying Clinical Research Sites: Deals and Due Diligence, 2025–2026

Published November 2026 — We identified more than 20 acquisitions, mergers, and investments involving clinical research sites and site networks between January 2025 and November 2026. This report lists them, summarizes what is known about valuation, and sets out what buyers examine before they commit.

Executive Summary

A Steady Market in Sites

Clinical research sites have become a recognized investment category. Over the past two years, buyers have ranged from large private equity firms acquiring whole networks to physician-owned groups adding one or two locations. This report draws on press releases, trade reporting, and adviser publications to describe that activity.

It is not a complete census. Many small transactions are never announced, and prices are rarely disclosed. Where a figure comes from an adviser with an interest in the market, or from press reports citing unnamed sources, we say so.

Key Findings

20+
Transactions Identified

Site and site-network deals announced between January 2025 and November 2026 that we could confirm from a published source.

~90%
Share Bought by Strategic Acquirers

Objective, an investment bank that advises on these sales, reports that strategic acquirers accounted for nearly 90% of site-related deals from 2021 to mid-2025. Many of those acquirers are themselves backed by private equity.

6–12x
Typical EBITDA Multiple

The same adviser puts site operators generally at 6 to 12 times EBITDA: 4 to 6 times for stand-alone sites under $5 million in EBITDA, rising to the low teens above $10 million.

~15%
Private Equity-Backed Share by 2024

An estimate attributed to Edgemont Partners puts about 30 private equity-backed platforms at roughly 15% of the Phase II–III site market by 2024, up from under 1% before 2014. We saw this figure only as cited by a third party.

The Deals

Transactions are grouped by type. Prices were not disclosed unless noted.

1

Whole Networks Changing Hands

BayPine agreed to acquire CenExel, a CNS-focused network with 18 U.S. locations and more than 1,200 staff, in April 2025, with Webster Equity retaining a minority. THL Partners agreed to buy Headlands Research from KKR in August 2025, at a price reported by Reuters as about $600 million. In August 2026, Advent International announced a majority investment in NZCR Group, which runs Phase I to IV research in New Zealand and Australia. In October 2026, Fengate Private Equity took a majority stake in Clinical Research of West Florida.

2

Networks Adding Sites

Flourish Research acquired Diablo Clinical Research in February 2025, bringing it to 26 sites. Rovia Clinical Research added StudyMetrix Research and Coastal Research Institute in September 2025. Alcanza bought Tampa Bay Medical Research in January 2026 and CNS Healthcare in June 2026, taking it past 30 locations. AMR Clinical acquired ClinOhio in June 2026. Headlands, under its new owner, bought Clinical Trials Research in California at mid-year. Summit Clinical Research Solutions acquired Dallas Research Institute in September 2026. Trade trackers also recorded single-site additions by ObjectiveHealth and Monroe Biomedical Research in December 2025.

3

Mergers and Carve-Outs

Paradigm Health acquired Flatiron Health's clinical research business in December 2025. FOMAT Medical Research bought the research-site unit of Topography Health in May 2026, giving it more than 35 sites in six states, while Topography continued as a technology company. Alliance Clinical Network and Atlas Clinical Research announced a merger in June 2026. Iterative Health acquired three Texas cardiology sites from NextStage Clinical Research in May 2026.

4

Beyond the United States

Panthera Biopartners, a UK site organization, made its first move into mainland Europe in April 2026 by acquiring OEC in Hungary, with four sites, more than 70 investigators, and more than 60 live trials. The Advent investment in NZCR Group is expected to close in the fourth quarter of 2026.

5

Smaller and Newer Buyers

Not every buyer is a fund. In November 2026, Equity Medical, a physician-owned group, bought a majority stake in Skylight Health Research, which has two sites, to reach eight locations. Growth investments in single sites and site management organizations were also recorded during the period.

6

What Is Not Known

We found no published data on how sites perform after they are acquired, on staff turnover following a deal, or on integration outcomes. Critics, including the Private Equity Stakeholder Project, argue that consolidation may affect trial safety and cost. Supporters argue that it funds infrastructure. Neither side has site-level evidence.

What Buyers Examine

Adviser and legal publications are consistent about what determines a site's value and what can reduce it.

Performance and Pipeline

Enrollment against timelines, the backlog of awarded studies not yet started, and therapeutic mix. Objective notes that oncology, CNS, and rare disease attract a premium.

Concentration

Dependence on a few sponsors or CROs, and above all on a single principal investigator, which the same adviser says constrains value.

Compliance History

Audit history, standard operating procedures, FDA Form 483s and warning letters. Unresolved FDA findings affect both value and deal terms, and sponsors routinely ask sites about them.

Conclusions

The market for clinical research sites was active throughout 2025 and 2026, across network sales, add-on acquisitions, mergers, and cross-border deals. Platforms assembled at single-digit multiples are, according to one adviser, often sold at mid-teens, which explains the continued interest.

The gap in this market is evidence. Buyers pay for enrollment performance, investigator depth, and clean compliance, yet these are hard to verify from outside and are measured differently by every seller. As more capital arrives, the buyers with the most reliable view of site quality will have the advantage.

Where SiteScore™ Fits

A Common Measure for Sites Under Review

SiteScore™ was built to make site quality comparable. Its five categories correspond closely to what buyers examine: execution covers enrollment, retention, and investigator experience; operational depth covers staffing and infrastructure; market access covers therapeutic coverage and patient reach; financial discipline covers operating history and budget adherence; and risk and compliance covers inspection history and deviation rates.

Investors can screen targets with a PreScore built from public data, request a document-verified Validated Score during diligence, and follow sites across a portfolio after closing.

Sources

This industry report is based on published announcements and industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative. Companies named are not Clinitiative clients unless stated.

See How SiteScore™ Works

Standardized, document-verified scoring for clinical research sites, used by sponsors, sites, and investors.